Literature DB >> 27329033

Attenuating the p53 Pathway in Human Cancers: Many Means to the Same End.

Amanda R Wasylishen1, Guillermina Lozano1.   

Abstract

The p53 pathway is perturbed in the majority of human cancers. Although this most frequently occurs through the direct mutation or deletion of p53 itself, there are a number of other alterations that can attenuate the pathway and contribute to tumorigenesis. For example, amplification of important negative regulators, MDM2 and MDM4, occurs in a number of cancers. In this work, we will review both the normal regulation of the p53 pathway and the different mechanisms of pathway inhibition in cancer, discuss these alterations in the context of the global genomic analyses that have been conducted across tumor types, and highlight the translational implications for cancer diagnosis and treatment.
Copyright © 2016 Cold Spring Harbor Laboratory Press; all rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27329033      PMCID: PMC4968169          DOI: 10.1101/cshperspect.a026211

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Med        ISSN: 2157-1422            Impact factor:   6.915


  134 in total

1.  Stabilization of the MDM2 oncoprotein by interaction with the structurally related MDMX protein.

Authors:  D A Sharp; S A Kratowicz; M J Sank; D L George
Journal:  J Biol Chem       Date:  1999-12-31       Impact factor: 5.157

2.  T antigen is bound to a host protein in SV40-transformed cells.

Authors:  D P Lane; L V Crawford
Journal:  Nature       Date:  1979-03-15       Impact factor: 49.962

3.  A small-molecule inhibitor of MDMX activates p53 and induces apoptosis.

Authors:  Hongbo Wang; Xujun Ma; Shumei Ren; John K Buolamwini; Chunhong Yan
Journal:  Mol Cancer Ther       Date:  2010-11-12       Impact factor: 6.261

4.  Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development.

Authors:  Shunbin Xiong; Carolyn S Van Pelt; Ana C Elizondo-Fraire; Geng Liu; Guillermina Lozano
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-21       Impact factor: 11.205

5.  Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage.

Authors:  R Khosravi; R Maya; T Gottlieb; M Oren; Y Shiloh; D Shkedy
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

Review 6.  Mutant p53 gain-of-function in cancer.

Authors:  Moshe Oren; Varda Rotter
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-02       Impact factor: 10.005

Review 7.  Prophylactic human papillomavirus vaccines: past, present and future.

Authors:  Lyndal A Anderson
Journal:  Pathology       Date:  2012-01       Impact factor: 5.306

8.  Amplification of a gene encoding a p53-associated protein in human sarcomas.

Authors:  J D Oliner; K W Kinzler; P S Meltzer; D L George; B Vogelstein
Journal:  Nature       Date:  1992-07-02       Impact factor: 49.962

9.  ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways.

Authors:  Y Zhang; Y Xiong; W G Yarbrough
Journal:  Cell       Date:  1998-03-20       Impact factor: 41.582

10.  Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53.

Authors:  S N Jones; A E Roe; L A Donehower; A Bradley
Journal:  Nature       Date:  1995-11-09       Impact factor: 49.962

View more
  54 in total

Review 1.  Negative auto-regulators trap p53 in their web.

Authors:  Xiang Zhou; Bo Cao; Hua Lu
Journal:  J Mol Cell Biol       Date:  2017-02-01       Impact factor: 6.216

2.  The p53 inhibitor Mdm4 cooperates with multiple genetic lesions in tumourigenesis.

Authors:  Shunbin Xiong; Vinod Pant; Yun Zhang; Neeraj K Aryal; M James You; Donna Kusewitt; Guillermina Lozano
Journal:  J Pathol       Date:  2017-01-06       Impact factor: 7.996

Review 3.  Genome Stability Requires p53.

Authors:  Christine M Eischen
Journal:  Cold Spring Harb Perspect Med       Date:  2016-06-01       Impact factor: 6.915

4.  Cancer: Acidic shield puts a chink in p53's armour.

Authors:  Michelle C Barton
Journal:  Nature       Date:  2016-09-14       Impact factor: 49.962

5.  Regulation of the Mdm2-p53 pathway by the ubiquitin E3 ligase MARCH7.

Authors:  Kailiang Zhao; Yang Yang; Guang Zhang; Chenfeng Wang; Decai Wang; Mian Wu; Yide Mei
Journal:  EMBO Rep       Date:  2018-01-02       Impact factor: 8.807

6.  p53 pathway dysfunction is highly prevalent in acute myeloid leukemia independent of TP53 mutational status.

Authors:  A Quintás-Cardama; C Hu; A Qutub; Y H Qiu; X Zhang; S M Post; N Zhang; K Coombes; S M Kornblau
Journal:  Leukemia       Date:  2016-11-25       Impact factor: 11.528

7.  Significant expression of CHK1 and p53 in bladder urothelial carcinoma as potential therapeutic targets and prognosis.

Authors:  Linfeng Zheng; Yuping Zhu; Lei Lei; Wenyong Sun; Guoping Cheng; Shifeng Yang
Journal:  Oncol Lett       Date:  2017-11-03       Impact factor: 2.967

8.  Etoposide radiosensitizes p53-defective cholangiocarcinoma cell lines independent of their G2 checkpoint efficacies.

Authors:  Arunee Hematulin; Sutiwan Meethang; Kitsana Utapom; Sopit Wongkham; Daniel Sagan
Journal:  Oncol Lett       Date:  2018-01-09       Impact factor: 2.967

9.  Cisplatin in Combination with MDM2 Inhibition Downregulates Rad51 Recombinase in a Bimodal Manner to Inhibit Homologous Recombination and Augment Tumor Cell Kill.

Authors:  Xiaolei Xie; Guangan He; Zahid H Siddik
Journal:  Mol Pharmacol       Date:  2020-02-16       Impact factor: 4.436

10.  Daxx Functions Are p53-Independent In Vivo.

Authors:  Amanda R Wasylishen; Jeannelyn S Estrella; Vinod Pant; Gilda P Chau; Guillermina Lozano
Journal:  Mol Cancer Res       Date:  2018-06-14       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.